Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Centene (NYSE:CNC) Share Price

Media stories about Centene (NYSE:CNC) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Centene earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5159834313631 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

Centene (CNC) opened at $100.88 on Tuesday. Centene has a 12 month low of $55.89 and a 12 month high of $104.65. The company has a quick ratio of 0.99, a current ratio of 0.99 and a debt-to-equity ratio of 0.71. The stock has a market cap of $17,408.51, a price-to-earnings ratio of 20.67, a P/E/G ratio of 1.45 and a beta of 0.70.

Centene (NYSE:CNC) last posted its earnings results on Tuesday, October 24th. The company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.11. Centene had a net margin of 1.81% and a return on equity of 14.79%. The business had revenue of $11.90 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period last year, the business posted $1.12 EPS. Centene’s revenue was up 9.7% compared to the same quarter last year. equities analysts anticipate that Centene will post 4.99 earnings per share for the current fiscal year.

A number of research firms have weighed in on CNC. Deutsche Bank reissued a “buy” rating and issued a $111.00 price objective (up from $95.00) on shares of Centene in a research report on Thursday, September 14th. Cantor Fitzgerald restated a “buy” rating and issued a $115.00 target price on shares of Centene in a research note on Monday, December 18th. Jefferies Group increased their price objective on shares of Centene from $112.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 18th. Oppenheimer raised their price target on shares of Centene from $111.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, December 20th. Finally, Zacks Investment Research upgraded shares of Centene from a “hold” rating to a “buy” rating and set a $107.00 price objective for the company in a report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Centene currently has a consensus rating of “Buy” and an average price target of $102.50.

In related news, Director Robert K. Ditmore sold 4,167 shares of Centene stock in a transaction dated Thursday, October 26th. The shares were sold at an average price of $90.42, for a total transaction of $376,780.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jesse N. Hunter sold 10,000 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $98.73, for a total transaction of $987,300.00. The disclosure for this sale can be found here. Company insiders own 3.00% of the company’s stock.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Centene (NYSE:CNC) Share Price” was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at

Centene Company Profile

Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company’s Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children’s Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.

Insider Buying and Selling by Quarter for Centene (NYSE:CNC)

Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply